Efficacy News and Research

RSS

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Research suggests that treatment with cisplatin plus S-1 together with thoracic radiotherapy is relatively efficacious and tolerable in patients with locally advanced non-small-cell lung cancer.

11 Dec 2014

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

11 Dec 2014

Progesterone treatment shows no clinical benefits in severe TBI patients

A study concluded that after five days of treatment with a novel formulation of progesterone acutely administered to patients with severe traumatic brain injury (TBI), showed no clinical benefits.

11 Dec 2014

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy.

10 Dec 2014

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report.

10 Dec 2014

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.

10 Dec 2014

E-cigarettes not as addictive as tobacco cigarettes

E-cigarettes appear to be less addictive than cigarettes in former smokers and this could help improve understanding of how various nicotine delivery devices lead to dependence, according to researchers.

10 Dec 2014

Report supports potential of focused ultrasound to treat certain OCD patients

A recently published report in the Journal of Molecular Psychiatry supports the potential of focused ultrasound to treat certain patients with obsessive-compulsive disorder (OCD).

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Patients with chronic myelogenous leukaemia resistant or intolerant to at least one second-generation tyrosine kinase inhibitor have a higher probability of achieving a response to the third-generation TKI ponatinib than to a further second-generation TKI, research indicates.

9 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles.

9 Dec 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.

9 Dec 2014

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively.

9 Dec 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR.

9 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.

8 Dec 2014

Efficacy News and Research

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Progesterone treatment shows no clinical benefits in severe TBI patients

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

PD-L1 expression tied to favourable prognosis in SCLC

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

E-cigarettes not as addictive as tobacco cigarettes

Report supports potential of focused ultrasound to treat certain OCD patients

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Triple hormone reduces body weight, improves insulin sensitivity

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News